Compare iShares MSCI Indonesia ETF (EIDO) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Indonesia ETF vs TG Therapeutics Inc — how do they compare? iShares MSCI Indonesia ETF trades at $11.89 (market cap $409.22M), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 19.9× iShares MSCI Indonesia ETF's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, iShares MSCI Indonesia ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Indonesia ETF for 76 Days and TG Therapeutics Inc for 16 Days on average.
| EIDO | TGTX | |
|---|---|---|
Market Cap | $409.22M | $8.16B |
Volume | 879,527 | 1,735,121 |
52-Week High | $19.22 | $59.06 |
52-Week Low | $10.80 | $26.94 |
Typical Hold Time | 76 Days | 16 Days |
Sector | — | Health |
Enterprise Value | — | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EIDO (iShares MSCI Indonesia ETF) trades at $11.89, up 0.25% with bearish technical signals from moving averages. The ETF faces headwinds from foreign capital outflows in Asian equities and limited upside from its heavy financials weighting. Recent news highlights Indonesia's underperformance despite commodity gains, with trading volume declining 21% below average.
Outlook remains cautious given technical downtrend and sector concentration risks. The ETF's bargain 8.7x P/E offers value but weak price action and low EPS growth constrain momentum. Key risks include regional capital rotation and dependence on financial sector performance.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
